{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(1)"],"submitter":["Opperman RM"],"funding":["Natural Sciences and Engineering Research Council of Canada","Canada Graduate Scholarships – Master’s program","Research Manitoba’s CFI Matching Fund","Lotte and John Hecht Memorial Foundation","Breast Cancer Canada","Research Manitoba masters studentship","Canada Foundation for Innovation","Canada Research Chairs"],"pubmed_abstract":["Doxorubicin is an effective treatment for breast cancer, but drug resistance poses a significant challenge. Emerging regulators of drug resistance include microRNAs, small non-coding RNAs. Two miRNAs, miR-526b and miR-655, promote aggressive breast cancer phenotypes like cell proliferation, cancer stem cell upregulation, altered response to oxidative and metabolic stress and help tumor metastasis by activating COX-2/EP4/PI3K pathways. However, their impact on the effects of chemotherapeutic treatments remains unexplored. This study investigates the impact of overexpressing miR-526b and miR-655 on doxorubicin responses in breast cancer, focusing on pro-survival, apoptotic, and DNA-damage response pathways. We confirm the role of PI3K/Akt signalling in promoting cell survival and resistance "],"journal":["Scientific reports"],"pagination":["33584"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12480915"],"repository":["biostudies-literature"],"pubmed_title":["Investigating the effects of miR-526b and miR-655 on doxorubicin sensitivity in breast cancer."],"pmcid":["PMC12480915"],"pubmed_authors":["Opperman RM","Majumder M","Maiti S"],"additional_accession":[]},"is_claimable":false,"name":"Investigating the effects of miR-526b and miR-655 on doxorubicin sensitivity in breast cancer.","description":"Doxorubicin is an effective treatment for breast cancer, but drug resistance poses a significant challenge. Emerging regulators of drug resistance include microRNAs, small non-coding RNAs. Two miRNAs, miR-526b and miR-655, promote aggressive breast cancer phenotypes like cell proliferation, cancer stem cell upregulation, altered response to oxidative and metabolic stress and help tumor metastasis by activating COX-2/EP4/PI3K pathways. However, their impact on the effects of chemotherapeutic treatments remains unexplored. This study investigates the impact of overexpressing miR-526b and miR-655 on doxorubicin responses in breast cancer, focusing on pro-survival, apoptotic, and DNA-damage response pathways. We confirm the role of PI3K/Akt signalling in promoting cell survival and resistance ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-07-15T09:49:49.782Z","creation":"2026-07-02T03:12:12.786Z"},"accession":"S-EPMC12480915","cross_references":{"pubmed":["41023167"],"doi":["10.1038/s41598-025-18719-y"]}}